** Goldman Sachs initiates UCB UCB.BR with a "buy" rating and a PT of 250 euros, saying the Belgian biopharmaceutical firm is a "rare opportunity" among European peers thanks to its skin disease drug Bimzelx
** The broker forecasts 7 billion euros ($8.14 billion) in peak sales for Bimzelx, underpinned by strong clinical data and initial launch momentum
** It sees the hidradenitis suppurativa market, a chronic skin disease, as a key opportunity where Bimzelx could become a market leader and drive upward consensus revenue revisions
** GS expects the drug to more than double UCB's revenue and quadruple its core profit (EBITDA) during the first 10 years to 2033
** Among the 20 analysts that cover UCB, 15 rate it "strong buy" or "buy," five "hold" and no analysts have "sell" or "strong sell" rating - LSEG data
($1 = 0.8604 euros)
(Reporting by Mathias de Rozario)
((mathias.derozario@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.